These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37722984)

  • 1. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
    Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
    Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
    Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
    Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
    J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
    Monteiro FSM; Soares A; Debiasi M; Schutz FA; Maluf FC; Bastos DA; Sasse A; Cauduro CGS; Mendes GO; Ziegelmann PK; Fay AP
    Clin Genitourin Cancer; 2020 Aug; 18(4):244-251.e4. PubMed ID: 32303427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma.
    Du EX; Betts KA; Wang T; Kitchen SA; He X; Yin X; Guttenplan SB; Beauchamp K; Delgado A; Rosenblatt L
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39127872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
    Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
    Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
    J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
    [No Abstract]   [Full Text] [Related]  

  • 9. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
    Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
    Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM
    Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
    Elaidi R; Phan L; Borchiellini D; Barthelemy P; Ravaud A; Oudard S; Vano Y
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32599839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
    Numakura K; Sekine Y; Hatakeyama S; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Kashima S; Yamamto R; Nara T; Akashi H; Tabata R; Sato S; Saito M; Narita S; Ohyama C; Habuchi T
    Cancer Med; 2023 Aug; 12(16):16837-16845. PubMed ID: 37403728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
    Tomida R; Takahashi M; Matsushita Y; Kojima T; Yamana K; Kandori S; Bando Y; Nishiyama N; Yamashita S; Taniguchi H; Monji K; Ishiyama R; Tatarano S; Masui K; Matsuda A; Kaneko T; Motoshima T; Shiraishi Y; Kira S; Murashima T; Hara H; Matsumura M; Kitamura H; Miyake H; Furukawa J;
    Clin Genitourin Cancer; 2024 Jun; 22(3):102094. PubMed ID: 38714434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
    Mantia CM; Jegede OA; Plimack ER; Powles T; Motzer RJ; Tannir NM; Lee CH; Tomita Y; Voss MH; Choueiri TK; Rini BI; Hammers HJ; Escudier B; Albigès L; Rosenblatt L; Atkins MB; Regan MM; McDermott DF
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
    Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
    Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T
    Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.